$NVCN im still holding for a run to +$3 On October 27 the FDA will hold a circulatory system devices panel meeting to review the premarket approval application for NVCN’s Reducer device. That catalyst should push the stock prices up even higher, which could give Neovasc stock the fuel to keep rallying.
  • 12
12 Likes